Hodgkin’s lymphoma: 2023 update on treatment

References

1. 1.↵
   2. Xu Z,
   3. Huang X.

   Cellular immunotherapy for hematological malignancy: recent progress and future perspectives. Cancer Biol Med. 2021; 18: 966–80.

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   2. Fornecker LM,
   3. Lazarovici J,
   4. Aurer I,
   5. Casasnovas RO,
   6. Gac AC,
   7. Bonnet C, et al.

   Brentuximab vedotin plus AVD for first-line treatment of early-stage unfavorable Hodgkin lymphoma (BREACH): a multicenter, open-label, randomized, phase II trial. J Clin Oncol. 2023; 41: 327–35.

   OpenUrl
3. 3.↵
   2. Herrera AF,
   3. LeBlanc M,
   4. Castellino SM,
   5. Li H,
   6. Rutherford SC,
   7. Evens AM, et al.

   Nivolumab(n)-Avd improves progression-free survival compared to brentuximab vedotin(BV)-Avd in advanced stage (AS) classic Hodgkin lymphoma (HL): results of SWOG S1826. Hematol Oncol. 2023; 41(S2): 33–5.

   OpenUrl
4. 4.↵
   2. Vinti L,
   3. Daw S,
   4. Alvarez CS,
   5. Fagioli F,
   6. Beishuizen A,
   7. Michel G, et al.

   S215: KEYNOTE-667: open-label, phase 2 study of pembrolizumab in children and young adults with newly diagnosed classical Hodgkin lymphoma (CHL) with slow early response to front-line chemotherapy. HemaSphere. 2023; 7(S3): e3506076.
5. 5.↵
   2. Borchmann P,
   3. Moccia AA,
   4. Greil R,
   5. Schneider G,
   6. Hertzberg M,
   7. Schaub V, et al.

   BRECADD is non-inferior to EBEACOPP in patients with advanced stage classical Hodgkin lymphoma: efficacy results of the GHSG phase III HD21 trial. Hematol Oncol. 2023; 41(S2): 881–2.

   OpenUrl
6. 6.↵
   2. Castellino SM,
   3. Pei Q,
   4. Parsons SK,
   5. Hodgson D,
   6. McCarten K,
   7. Horton T, et al.

   Brentuximab vedotin with chemotherapy in pediatric high-risk Hodgkin’s lymphoma. N Engl J Med. 2022; 387: 1649–60.

   OpenUrl
7. 7.↵
   2. Herrera AF,
   3. Chen L,
   4. Nieto Y,
   5. Holmberg L,
   6. Johnston P,
   7. Mei M, et al.

   Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial. Lancet Haematol. 2023; 10(1): e14–23.

   OpenUrl
8. 8.↵
   2. Liu W,
   3. Lin N,
   4. Feng X,
   5. Xie Y,
   6. You C,
   7. Zhou X, et al.

   Long-term survival benefit of anti-PD-1 therapy in patients with relapsed or refractory classical Hodgkin lymphoma. Signal Transduct Target Ther. 2023; 8: 356.

   OpenUrl
9. 9.↵
   2. Harker-Murray P,
   3. Mauz-Körholz C,
   4. Leblanc T,
   5. Mascarin M,
   6. Michel G,
   7. Cooper S, et al.

   Nivolumab and brentuximab vedotin with or without bendamustine for R/R Hodgkin lymphoma in children, adolescents, and young adults. Blood. 2023; 141: 2075–84.

   OpenUrl
10. 10.↵
    2. Zhang H,
    3. Yu J,
    4. Li H,
    5. Qian W,
    6. Xiao X,
    7. Cai Q, et al.

    S216: CD47/PD-L1 bispecific antibody (IBI322) in anti-PD-1 or PD-L1 treatment-resistant classical Hodgkin lymphoma: a phase I study. HemaSphere. 2023; 7(S3): e8102841.
11. 11.↵
    2. Ramos CA,
    3. Quach DH,
    4. Lulla PD,
    5. Rouce RH,
    6. Sharma S,
    7. Ganesh HR, et al.

    Off-the-shelf CD30.CAR-modified Epstein-Barr virus-specific T cells (CD30.CAR EBVSTS) provide a safe and effective therapy for patients with Hodgkin lymphoma (HL). Hematol Oncol. 2023; 41(S2): 83–5.

    OpenUrl
12. 12.↵
    2. Dickinson MJ,
    3. Trotman J,
    4. Berkahn L,
    5. Butler J,
    6. Bressel M,
    7. Neeson P, et al.

    Pembrolizumab as first therapy for Hodgkin lymphoma is deliverable in older or ABVD-ineligible patients, allows subsequent therapy, and gives adequate survival. Hematol Oncol. 2023; 41(S2): 160–1.

    OpenUrl
13. 13.↵
    2. Torka P,
    3. Feldman T,
    4. Savage K,
    5. Ganesan N,
    6. Hancock H,
    7. Davey T, et al.

    Phase 2 trial of nivolumab plus adriamycin, vinblastine, dacarbazine (N-AVD) as frontline therapy in older adults with Hodgkin lymphoma. Hematol Oncol. 2023; 41(S2): 161–2.

    OpenUrl
14. 14.↵
    2. Lynch RC,
    3. Ujjani CS,
    4. Poh C,
    5. Warren EH,
    6. Smith SD,
    7. Shadman M, et al.

    Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma. Blood. 2023; 141: 2576–86.

    OpenUrl
15. 15.↵
    2. Wang Y,
    3. Huang R,
    4. Wang Z,
    5. Xiong J,
    6. Wang X,
    7. Zhang X.

    Facing challenges with hope: universal immune cells for hematologic malignancies. Cancer Biol Med. 2023; 20: 229–47.

    OpenUrlAbstract/FREE Full Text